Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2009-013398-16 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hospital de Santa Maria, Portugal | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To determine the efficacy and Security of Thymoglobuline in cadaveric donor Efficacy: To demonstrate that in cadaveric donor, Thymoglobuline diminished graft alloreactivity by decreasing expression of inflammatory markers in graft biopsies Security:To demonstrate that the administration of Thymoglobulin does not have side effects in renal recipients.
This is randomized controlled Multicenter phase II clinical trial promoted by members from IdiPAZ. At least two hospital (La Paz and Santa Maria from Lisbon, will be involved. A per nature pilot study will recruit 10 cadaver donors from each hospital, and randomized half-to-half per center, for study and control groups.
The RCT initiated in 2009 and finished in 2013.
Cadaver donor from the study group will receive 3 mg/kg iv. Thymoglobulin 3-6 hours prior to organ procurement. The randomization process recruits 1:1 study/control donors.
Kidney biopsies will be taken from each kidney before transplantation to examine the expression of pro-inflammatory and HLA molecules (anti-DR, VCAM, ICAM, E-selectin) at tubular cells by immunohistochemical techniques under blinded conditions.
Recipients will be managed as usual and expressly followed up for one year, recording the incidence of delayed graft function and rejection and graft survival at the first year.
A comparison between the results obtained in kidney biopsies and patients transplanted in each group will permit differentiate whether Thymoglobulin administered in cadaver modifies the expression of antigens by kidney tubular cells and the results obtained with transplantation, in terms of graft function, rejection and survival.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non treated | Placebo Comparator | Cadaver donor is cared and treated as usual protocol | |
| TREATED | Experimental | Cadaver donor receives one dose of thymoglobulin of 3 mg/kg iv in 2 hours after ganglia extraction and 3- 6 hours prior to organ procurement. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Thymoglobulin | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy of Thymoglobuline in cadaveric donor | To determine the efficacy of Thymoglobuline in cadaveric donor Efficacy: To demonstrate that in cadaveric donor, Thymoglobuline diminished graft alloreactivity by decreasing expression of inflammatory markers(determining HLA-DR,VCAM-1, ICAM-1 expressions by immunohistochemistry in graft biopsies), and the rates of delayed graft function and cellular/humoral rejection demonstrated by biopsy. | 2 days |
| Security of Thymoglobuline in cadaveric donor | Estimated by general and particularly hemodynamic tolerance to thymoglobulin infusion. | 1 day |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of acute rejection in the recipients | To demonstrate that in cadaveric donors, Thymoglobuline tends to decrease the incidence of acute rejection demonstrated by kidney biopsy. | 3 moths |
| Incidence of delayed graft function in the recipients. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Carlos Jimenez, MD, PhD | Hospital Universitario La Paz | Principal Investigator |
| Maria Lopez-Oliva, MD | Hospital Universitario La Paz | Principal Investigator |
| Rui Mayo, MD | Hospital Santa Maria, Portugal | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Santa Maria | Lisbon | Lisbon District | 1649-035 | Portugal | ||
| Hospital Universitario La Paz |
Not provided
| Label | URL |
|---|---|
| Medical Research Institute | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| C512542 | thymoglobulin |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To demonstrate that in cadaveric donors, Thymoglobuline tends to decrease the incidence of DGF estimated by the necessity of dialysis after transplantation.
| 1 month |
| Composite of incidence of graft function and general effects in the recipients. | To demonstrate that Thymoglobuline administered in cadaveric donors does not have neither repercussion on graft function nor side effects in renal and liver recipients. | 1 year |
| Madrid |
| Madrid |
| 28046 |
| Spain |